An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
VERDICT
The label
Markdown
read at $104.13
Insmed Inc holds its Markdown at $104.13.
PHPhase · the trend structure carries the Markdown label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-29
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 19 days
Price
$104.13
Valuation
N/A trailing · 811.68 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.78
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$104.13
N/A P/E · 811.68 fwd
Our fair value
$100.16
4% premium
Analyst target (avg)
$197.50
+90% to current
Target low $140.00Analyst target rangeTarget high $243.00
▲ current $104.13 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$104.13
you are here
Conservative
$100.16
-4%
Analyst avg
$197.50
+90%
Our fair value
$100.16
-4%
Analyst high
$243.00
+133%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
Revenue growth
229.60%
Profit margin
-144.44%
Debt to equity
105.34
Analyst consensus
Strong Buy · 22 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purity of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Rare disease biotech priced for perfection
A patient in Japan finally clearing a stubborn lung infection marks real progress for families who had few options before. Insmed is delivering that progress, with revenue up 230 percent as its lead therapy gains ground across the US, Europe and Japan.
Yet the shares sit 6 percent above our fair value at an 814 times forward multiple while margins sit at minus 144 percent and return on equity at minus 294 percent. Narrow moat and strong buy analyst targets do not change the fact that current pricing leaves almost no margin of safety.
Execution risk in rare disease trials, regulatory delays abroad and the need to turn rapid top line growth into actual profits remain the central concerns. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADER
The trader read · the latest dated commentary
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197. Entered 2026-07-18 · Distribution
JOURNAL
The dated journal · newest first, never edited
2026-07-18Distribution$97.85+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197.
2026-07-03Distribution$97.85+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$97.85Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$103.89
-12.0%
·
$880
-12.0%
2 months
$154.81
-41.0%
·
$590
-41.0%
3 months
$139.52
-34.5%
·
$655
-34.5%
6 months
$195.24
-53.2%
·
$468
-53.2%
1 year
$90.93
+0.5%
·
$1,005
+0.5%
2 years
$59.90
+52.6%
·
$1,526
+52.6%
3 years
$19.80
+361.5%
·
$4,615
+361.5%
5 years
$30.06
+204.0%
·
$3,040
+204.0%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever INSM does next, these words stay.
Insmed Inc · INSM · Markdown · $104.13
Recorded 2026-07-29 · before the outcome · scored mechanically
